Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease
Open Access
- 1 August 2000
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 26 (4) , 445-449
- https://doi.org/10.1038/sj.bmt.1702518
Abstract
Although allogeneic transplantation can be curative for patients with sickle cell disease, the toxicity of conditioning regimens has precluded its use in adults with significant end-organ damage. Newer conditioning regimens have been developed that are less toxic and that may broaden the applicability of allogeneic transplantation in this disorder. We report two adults with end-stage sickle cell disease, who underwent allogeneic transplantation from an HLA-identical sibling donor after conditioning with fludarabine/melphalan and ATG. Both patients had been extensively transfused and one had multiple RBC antibodies. One of the patients also had end-stage renal disease, and was dialysis dependent. Engraftment occurred promptly in both patients. Both achieved 100% donor chimerism and both were free of pain crises after transplant. The first patient died of a respiratory failure related to chronic graft-versus-host disease (GVHD) on day 335 after transplantation. The second patient developed severe gastro-intestinal GVHD and TTP and died on day 147 after transplantation. Conditioning with fludarabine/melphalan and ATG followed by allogeneic stem cell transplantation resulted in prompt and reliable engraftment in adults with end-stage sickle cell disease. The incidence of severe GVHD was unacceptably high and may be related to the ethnicity of the patients or to the inflammatory state associated with pre-existing sickle cell disease. Bone Marrow Transplantation (2000) 26, 445–449.Keywords
This publication has 14 references indexed in Scilit:
- Mixed chimerism: Preclinical studies and clinical applicationsTransplantation and Cellular Therapy, 1999
- STEM CELL TRANSPLANTATION FOR A HIGHLY SENSITIZED PATIENTTransplantation, 1999
- Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in BelgiumBone Marrow Transplantation, 1998
- Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic DiseasesBlood, 1998
- Effective clearance of methotrexate using high-flux hemodialysis membranesAmerican Journal of Kidney Diseases, 1996
- ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIATransplantation, 1996
- Bone Marrow Transplantation for Sickle Cell DiseaseNew England Journal of Medicine, 1996
- Bone Marrow Transplantation in Sickle Cell Anemia — The Dilemma of ChoiceNew England Journal of Medicine, 1996
- Improved survival in homozygous sickle cell disease: lessons from a cohort studyBMJ, 1995
- Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early DeathNew England Journal of Medicine, 1994